News

SDIX has posted a net loss of $29,000 for the third quarter 2010, or $0 loss per diluted share, compared to net loss of $291,000 or $0.01 loss

The clinical research program will be led by Jeffrey Stout, MusclePharm’s scientific advisor, who will study the effects of MusclePharm’s products on high-intensity interval training, on aerobic and

The VersiDoser delivery platform is said to be a liquid delivery platform that comprises novel unit dose blister packaging, proprietary intranasal and ophthalmic delivery devices and aseptic manufacturing

The in-vivo maximisation sensitisation test method is designed to evaluate the allergenic potential or sensitising capacity of DispersinB wound spray. According to the company, the biocompatibility results confirm

Kendle has posted a net income of $1.55m for the third quarter 2010, or $0.1 per diluted share, compared to net income of $8.83m, or $0.59 per diluted

BDI’s portfolio includes branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or hyper immune globulins and other specialty injectables. BDI IT VP Tim

The patented, gene expression test uses a simple, noninvasive method of blood sample collection and can show the low probability of acute cellular rejection in stable heart transplant

The addition of MedAppz’ iSuite EHR broadens MedLink’s technology offerings, enabling the company to provide a web-based solution built on the latest Microsoft .Net 4.0 platform. MedAppz claims

Mitsui has invested $12.5m in cash in return for new convertible Preference Shares giving Mitsui 12.2% of the enlarged share capital of Hutchison MediPharma. Mitsui Global Investment Department